Growth Metrics

Moderna (MRNA) EPS (Basic) (2017 - 2025)

Moderna (MRNA) has disclosed EPS (Basic) for 9 consecutive years, with -$2.11 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Basic) rose 27.49% to -$2.11 in Q4 2025 year-over-year; TTM through Dec 2025 was -$7.26, a 21.68% increase, with the full-year FY2025 number at -$7.26, up 21.77% from a year prior.
  • EPS (Basic) was -$2.11 for Q4 2025 at Moderna, down from -$0.5 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $12.06 in Q4 2021 to a low of -$9.53 in Q3 2023.
  • A 5-year average of $1.13 and a median of $0.12 in 2023 define the central range for EPS (Basic).
  • Peak YoY movement for EPS (Basic): soared 2335.48% in 2021, then tumbled 1635.0% in 2024.
  • Moderna's EPS (Basic) stood at $12.06 in 2021, then plummeted by 68.08% to $3.85 in 2022, then crashed by 84.68% to $0.59 in 2023, then crashed by 593.22% to -$2.91 in 2024, then grew by 27.49% to -$2.11 in 2025.
  • Per Business Quant, the three most recent readings for MRNA's EPS (Basic) are -$2.11 (Q4 2025), -$0.5 (Q3 2025), and -$2.13 (Q2 2025).